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INTRODUCTION AND AIMS:Diabetic nephropathy (DN) is the leading cause of
CKD in the Western world. Around 50 percent of patients who have had diabetes for
more than 20 years develop CKD. Glomerulosclerosis and tubulointerstitial ﬁbrosis are
histological features as DN progresses towards end-stage renal disease. Fibrosis is char-
acterized by a dysregulated remodeling of the extracellular matrix (ECM). Collagen
type VI (COL VI) is a crucial ECM molecule for the control of tissue organization. It is
present at the interface of the glomerular basement membrane and interstitial matrix
and its levels have been reported elevated in glomeruli of patients with glomerular dis-
eases and in the mesangium of diabetic patients. During deposition of COL VI, a frag-
ment is released, namely endotrophin (ETP). Endotrophin (ETP), has shown pro-
ﬁbrotic potential. We investigated the prognostic potential of COL VI formation and
ETP for CKD progression by measuring baseline levels in urine and plasma from
patients with DN.
METHODS: COL VI formation and ETP were measured using a novel enzyme-linked
immunosorbent assay targeting the C-terminal end of the a3 chain of COL VI (Pro-
C6). Patients with type 1 or 2 diabetes receiving renin angiotensin system inhibitors
were included if they had serum creatinine concentrations between 1.3 to 3.5 mg/dl (or
estimated glomerular ﬁltration rate (eGFR) between 20 to 60 mL/min/1.73 m2) or a 24-
hour urine protein/creatinine ratio (PCR) 800 mg/g. Paired urine and plasma base-
line samples from 99 DN patients who participated in a one year therapeutic clinical
study (NCT01113801). Urinary Pro-C6 was normalized to urinary creatinine. The out-
come of interest was change of eGFR (calculated with the MDRD formula) from base-
line to 9 and 12 months.
RESULTS: Levels of Pro-C6 in both plasma and urine correlated with eGFR at baseline,
9 month, and 12 months (all p<0.0001). Moreover, urinary Pro-C6 correlated with
change in eGFR at 9 and 12 months (both p<0.01). Whereas levels of Pro-C6 in urine
correlated signiﬁcantly with PCR (p<0.0001) no correlation between plasma Pro-C6
and PCR was observed (p=0.99). Urinary Pro-C6 was independently associated with
decrease in eGFR at both 9 months (r=-0.335, p<0.01) and 12 months (r=-0.358,
p<0.01) even after adjustment for eGFR and PCR. When patients were divided into
quartiles based on their rate of eGFR change over 12 months, urinary Pro-C6 adjusted
for baseline eGFR and PCR was able to separate the fastest progressing patients with an
AUC of 0.732 (p<0.001).
CONCLUSIONS:We found a signiﬁcant association between the Pro-C6 marker of
COL VI formation and CKD progression in patients with DN, independent of baseline
eGFR and proteinuria. Because the Pro-C6 assay cross-reacts with the matrikine endo-
trophin, these results might suggest a role for endotrophin in disease progression.
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INTRODUCTION AND AIMS: Patients with chronic kidney disease (CKD) have
increased risk of progressing to end-stage renal disease (ESRD) and a high mortality
rate. One of the major underlying causes of progression of renal failure is renal ﬁbrosis,
which is caused by dysregulated extracellular matrix (ECM) remodeling. The laminin
c1 (LAMC1) chain is a constituent of the laminin types present in the glomerular base-
ment membrane (GBM), and its turnover may be altered in CKD. Fragments of
LAMC1 could quantify GBM turnover in human CKD and reﬂect pathological
tissue changes. We developed an immunoassay targeting LG1M, a neo-epitope of
LAMC1 generated by matrix metalloproteinases (MMPs). We then measured
LG1M levels in serum and urine from a large prospective cohort of patients with high-
risk CKD.
METHODS: A novel immunoassay targeting a speciﬁc MMP-9-generated neo-epitope
fragment of LAMC1 (LG1M) was used to measure the fragment levels in urine and
serum from 492 patients from the Renal Impairment in Secondary Care (RIISC) study,
a prospective cohort of patients with high-risk CKD. Patients were monitored for a
median follow-up time of 2.5 years. Progression of CKD was deﬁned as a decline in
eGFR of more than 30%, or starting renal replacement therapy as a deﬁnition of end-
stage-renal disease (ESRD) within 12 months. Associations between LG1M levels in
both serum and urine for progression of CKD were assessed by a multivariable logistic
regression model with forward selection, while adverse outcomes were assessed by
Kaplan-Meier and Cox regression analysis.
RESULTS: Forty-six patients (11%) of 411 patients who were alive and under follow-
up at 12 months had progressed. During the study 102 patients developed ESRD and
65 patients died. Both urinary and serum levels of LG1M showed an inverse linear cor-
relation with baseline eGFR (Spearman’s correlation coefﬁcient r=-0.43, p<0.0001 and
r=-0.17, p=0.0002, respectively). Serum but not urinary LG1M levels were signiﬁcantly
associated with progression of CKD within 12 months (p<0.01), but were not included
in the ﬁnal model for prediction of whether the patients developed ESRD. Urinary
LG1M levels were signiﬁcantly associated with death; patients in the highest LG1M ter-
tile were 4.5 (p<0.0001) times more likely to die than patients in the ﬁrst tertile.
Urinary LG1M levels were included in the ﬁnal model for prediction of mortality (HR
1.25, 95% CI 1.04-1.51, p=0.02).
CONCLUSIONS: The novel biomarker LG1M reﬂecting glomerular basement
membrane remodeling is associated with disease progression, development of ESRD,
and mortality in high-risk CKD patients.
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INTRODUCTION AND AIMS:Nowadays, many proteomic studies in the context of
CKD are focused on investigating molecular alterations present in patients with fast
diseases progression as compared to stable ones. Conversely, we focused on patients
showing GFR improvement, which may give some insight in possible mechanisms of
the disease remission and/or regression. Our aim was to identify urinary peptides
associated with improvement in estimated glomerular ﬁltration rate (eGFR) over time
and to develop a multidimensional-based classiﬁer combining urinary peptides identi-
ﬁed by capillary electrophoresis coupled to mass spectrometry (CE-MS) methodology
to enable identiﬁcation of patients with improvement in eGFR.
METHODS: CE-MS has been extensively used as an analytical platform for discover-
ing and validating biomarkers for CKD. With this approach, we analyzed urine samples
from patients with various renal diseases. eGFR was calculated using CKD-EPI equa-
tion and the slope/year (ml/min/1.73m2/year) was calculated by linear regression anal-
ysis based on at least 3 data points and 3 years follow up (FU) time. Percent change of
slope/year (%slope/year) was calculated as a percent change from baseline eGFR, and
used as selection criteria for stratifying patients into two groups. In total, 376 patients
with %slope/year between -1.5% and +1.5% were assigned as non-progressors or stable,
and 177 patients with> 5% slope/year as patients with improvement of eGFR (renal
function). From the total number of the stratiﬁed patients, 75% were randomly used
for biomarker discovery and deﬁned as development cohort whereas the remaining
25% were used as validation cohort.
RESULTS: Statistical analysis with CE-MS data of the urine samples from development
cohort resulted in identiﬁcation of 384 peptide fragments that were signiﬁcantly differ-
ent between the stable and patients with improved renal function. Out of these, the
most signiﬁcant 141 peptide fragments were used for generation of the Support Vector
Macine (SVM)-based classiﬁcation panel. The biomarker panel was applied to our vali-
dation cohort, achieving moderate area under the curve (AUC) of 0.80 with sensitivity
and speciﬁcity of 77% and 70%, respectively. In our next approach, using tandemmass
spectrometry (MS/MS) we retrieved sequence information for all small peptide frag-
ments included in the diagnostic multimarker panel, and most of them (78%) were
belonging to different collagen types. With further literature analysis of the 31 non-
collagen peptides included into the classiﬁer, we observed that fragments from 7 pro-
teins associated with different kidney diseases and CKD progression, have demon-
strated opposite regulation.
CONCLUSIONS:We have developed an urinary peptide marker panel for
discrimination of patients predisposed to improve their kidney function over time and
possibly treat them with less aggressive speciﬁc or supportive therapy. Thus, we
hypothesize that downregulation of above mentioned CKD-related proteins in patients
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